SSPLAXLife Sci
Clinical, manufacturing, and release decisions under hard capacity and timing limits.
Clinical Supply Coverage
Will released supply stay ahead of enrollment over the trial, and where does coverage first break?
A clinical-stage program supplies an active Phase 2 trial. Drug substance comes from a primary CDMO plus a higher-cost backup slot, then moves through drug product, fill–finish, QC release, and QA disposition. Released kits enter an inventory buffer before they are allocated to sites. Enrollment changes month by month, so early released supply can cover later demand only if the buffer stays ahead of the ramp.
CMC LaunchBiologics Tech Transfer
When every team is busy, which gate is really on the launch critical path?
A late-stage biologics program is moving from a donor site to a receiving CDMO ahead of launch. The technical package, analytical method transfer, comparability work, engineering lots, PPQ campaign, validation report, and CMC variation all have to clear in sequence. The calendar looks busy everywhere, but not every busy workstream protects the launch date.
BioprocessRelease Throughput
Useful output is below plan: which stage is limiting it, and which capacity change increases output first?
Released output has fallen below the manufacturing plan after several operating changes. Fed-batch and perfusion still feed a shared purification, fill/finish, and release path, and leadership has budget for one recovery move. The competing proposals are more upstream runs, additional downstream capacity, extra fill/finish slots, or outsourced processing.